Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Eli Lilly ( LLY 0.86%) is a screaming buy because it makes the most potent weight-loss drug that's on the market right now, ...

Americans pay more for health care but don't get better results. Why? The blame goes well beyond insurance companies.

All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent ...

The weight-loss drug Ozempic could increase the risk of vision loss, a new study found. Ozempic has been hailed as a ...